Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anagrelide in primary thrombocythemia].

H Knutsen1, J Hysing

  • 1Medisinsk avdeling Sentralsykehuset i Akershus 1474 Nordbyhagen. havar.knutsen@chello.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|July 14, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of aggregated exposure to perfluorooctanoic acid (PFOA) from diet and personal care products with concentrations in blood using a PBPK model - Results from the Norwegian biomonitoring study in EuroMix.

Environmental research·2023
Same author

Are low but statistically significant levels of genetic differentiation in marine fishes 'biologically meaningful'? A case study of coastal Atlantic cod.

Molecular ecology·2011
Same author

Genetic diversity within and among Atlantic cod (Gadus morhua) farmed in marine cages: a proof-of-concept study for the identification of escapees.

Animal genetics·2010
Same author

Fine-scaled geographical population structuring in a highly mobile marine species: the Atlantic cod.

Molecular ecology·2003
Same author

Genetic evidence for mixed origin of recolonized sea trout populations.

Heredity·2001
Same author

Genetic differentiation among populations of the beetle Bolitophagus reticulatus (Coleoptera: tenebrionidae) in a fragmented and a continuous landscape.

Heredity·2000

Anagrelide effectively lowers platelet counts in essential thrombocythaemia patients under 60. This platelet-lowering agent demonstrated good tolerability and efficacy, making it a potential treatment of choice.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Essential thrombocythaemia (ET) is a myeloproliferative neoplasm characterized by elevated platelet counts (>600 x 10(9)/l).
  • ET increases the risk of thromboembolic events.
  • Anagrelide is a platelet-lowering agent used in ET management.

Observation:

  • A study evaluated anagrelide treatment in ten ET patients under 60 years old (1997-2000).
  • Nine patients had prior treatment, primarily with hydroxyurea.
  • Three patients were asymptomatic at the time of treatment initiation.

Findings:

  • Anagrelide treatment, with gradual dose escalation and hydroxyurea reduction, normalized platelet counts (<500 x 10(9)/l) in seven patients.
  • Common side effects included transient headache, palpitations, and diarrhea.

Related Experiment Videos

  • Two patients discontinued anagrelide due to side effects; one reduced the dose for palpitations.
  • No vascular complications were reported during the study period.

    • Implications:

    • Anagrelide is an effective treatment for essential thrombocythaemia in patients under 60.
    • The drug exhibits a favorable side effect profile in this patient group.
    • Anagrelide warrants consideration as a primary therapeutic option for younger ET patients.